Overview

Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis

Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the microbiological and clinical efficacy of Auriclosene compared to its vehicle for bacterial conjunctivitis. Adults and children one year of age and older with bacterial conjunctivitis in at least one eye may be eligible. Subjects will be randomly assigned to receive either Auriclosene Ophthalmic Solution or Vehicle Ophthalmic Solution.
Phase:
Phase 2
Details
Lead Sponsor:
NovaBay Pharmaceuticals, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions